Brand name: Auvi-Q
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
cinqaero - Twitter Search / Twitter
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study - The Journal of Allergy and Clinical Immunology: In Practice
Cinqair (reslizumab): Basics, Side Effects & Reviews
A Guide to the Prescription and Service Request Form
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Reslizumab - wikidoc
Injectable asthma drug reslizumab approved by European Commission - The Pharmaceutical Journal
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab – All About Drugs
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Reslizumab
Teva files MAA for asthma treatment reslizumab
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Israeli Pharma gets FDA Approval for Asthma Antibody
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
